Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NUVLNASDAQ:SDGRNASDAQ:TGTXNASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$76.06-0.3%$73.10$55.54▼$113.51$5.46B1.34492,448 shs424,404 shsSDGRSchrödinger$20.88-1.5%$23.70$16.60▼$28.47$1.53B1.63901,615 shs1.28 million shsTGTXTG Therapeutics$35.00-1.8%$37.24$16.21▼$46.48$5.56B1.942.96 million shs1.70 million shsTLXTelix Pharmaceuticals Limited American Depositary Shares$16.65-0.5%$17.01$13.61▼$30.36$5.63BN/A25,847 shs4,212 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent-2.45%+0.32%+4.09%-0.44%-1.88%SDGRSchrödinger-1.07%-16.76%-10.09%-7.42%+2.76%TGTXTG Therapeutics-1.06%-10.57%+3.70%-10.66%+115.29%TLXTelix Pharmaceuticals Limited American Depositary Shares+4.04%-1.01%+0.36%-3.24%+1,673,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNUVLNuvalent2.3444 of 5 stars3.52.00.00.02.23.30.0SDGRSchrödinger2.4982 of 5 stars3.51.00.00.03.12.50.6TGTXTG Therapeutics3.5531 of 5 stars2.41.00.03.51.62.51.9TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNUVLNuvalent 2.90Moderate Buy$115.5051.85% UpsideSDGRSchrödinger 3.00Buy$32.8057.09% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.8016.57% UpsideTLXTelix Pharmaceuticals Limited American Depositary Shares 3.00Buy$22.0032.13% UpsideCurrent Analyst Ratings BreakdownLatest SDGR, TLX, TGTX, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025TLXTelix Pharmaceuticals Limited American Depositary SharesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.006/5/2025TLXTelix Pharmaceuticals Limited American Depositary SharesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/ASDGRSchrödinger$230.49M6.65$0.56 per share37.42$7.60 per share2.75TGTXTG Therapeutics$386.39M14.38$0.10 per share353.90$1.06 per share33.02TLXTelix Pharmaceuticals Limited American Depositary Shares$783.21M7.19N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNUVLNuvalent-$126.22M-$4.39N/AN/AN/AN/A-28.63%-27.15%8/14/2025 (Estimated)SDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)TGTXTG Therapeutics$12.67M$0.24N/A35.00N/A-5.42%-8.32%-3.40%8/5/2025 (Estimated)TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/A0.0034.69N/AN/AN/AN/AN/ALatest SDGR, TLX, TGTX, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNUVLNuvalentN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNUVLNuvalentN/A23.0723.07SDGRSchrödingerN/A4.114.11TGTXTG Therapeutics1.274.593.91TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNUVLNuvalent97.26%SDGRSchrödinger79.05%TGTXTG Therapeutics58.58%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AInsider OwnershipCompanyInsider OwnershipNUVLNuvalent10.20%SDGRSchrödinger8.60%TGTXTG Therapeutics10.64%TLXTelix Pharmaceuticals Limited American Depositary SharesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNUVLNuvalent4071.81 million62.16 millionOptionableSDGRSchrödinger79073.38 million66.59 millionOptionableTGTXTG Therapeutics290158.76 million139.32 millionOptionableTLXTelix Pharmaceuticals Limited American Depositary SharesN/A338.11 millionN/AN/ASDGR, TLX, TGTX, and NUVL HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Trading Down 6.7% - Here's What HappenedJune 15 at 4:07 AM | americanbankingnews.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price Down 6.7% - Time to Sell?June 13, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)June 13, 2025 | americanbankingnews.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares' (TLX) "Outperform" Rating Reaffirmed at WedbushJune 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Here's What HappenedJune 8, 2025 | americanbankingnews.comWilliam Blair Has Bullish Estimate for TLX FY2025 EarningsJune 8, 2025 | americanbankingnews.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Coverage Initiated by Analysts at WedbushJune 7, 2025 | americanbankingnews.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?June 6, 2025 | marketbeat.comWilliam Blair Has Positive Estimate for TLX FY2025 EarningsJune 6, 2025 | marketbeat.comWedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform RecommendationJune 5, 2025 | msn.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's WhyJune 5, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Now Covered by WedbushJune 5, 2025 | marketbeat.comTelix Investor Day in New York City on June 11, 2025: Presenting KOLsJune 3, 2025 | globenewswire.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's What HappenedMay 31, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Up 11.4% - What's Next?May 25, 2025 | marketbeat.comTelix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging EfficacyMay 7, 2025 | globenewswire.comShareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLXMay 7, 2025 | accessnewswire.comATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your RightsMay 6, 2025 | accessnewswire.comTelix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)May 5, 2025 | accessnewswire.comTelix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)May 2, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSDGR, TLX, TGTX, and NUVL Company DescriptionsNuvalent NASDAQ:NUVL$76.06 -0.26 (-0.34%) Closing price 04:00 PM EasternExtended Trading$76.10 +0.03 (+0.05%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Schrödinger NASDAQ:SDGR$20.88 -0.32 (-1.51%) Closing price 04:00 PM EasternExtended Trading$20.99 +0.11 (+0.53%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.TG Therapeutics NASDAQ:TGTX$35.00 -0.63 (-1.77%) Closing price 04:00 PM EasternExtended Trading$35.34 +0.34 (+0.99%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX$16.65 -0.09 (-0.54%) Closing price 03:57 PM EasternExtended Trading$16.58 -0.07 (-0.42%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
